Health

Novavax COVID-19 vaccine

On June 14, Reuters was 15 seconds ahead in reporting that Novavax’s COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

Market Impact

Shares of the U.S.-based company jumped more than 7% on the news.



Article Tags
Topics of Interest: Health
Type: Reuters News First
Sectors: Pharmaceuticals & Healthcare
Regions: Americas
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Subscribe
Sign up for email updates